Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PELF (cisplatin + epirubicin + leucovorin + 5-fluorouracil)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
PELF is a combination chemotherapy regimen consisting of cisplatin, epirubicin, leucovorin, and 5-fluorouracil. It was developed as a treatment for advanced gastric carcinoma. Clinical trials have shown PELF to be significantly more active than other regimens like FAMTX (5-fluorouracil, doxorubicin, and methotrexate) in terms of complete response rates and objective response rates. The regimen works through multiple mechanisms: cisplatin forms DNA crosslinks inhibiting replication, epirubicin intercalates with DNA and inhibits topoisomerase II, leucovorin enhances 5-FU activity, and 5-fluorouracil inhibits thymidylate synthase disrupting DNA synthesis.
- Other names
- Cisplatin, Epirubicin, Leucovorin and 5-Fluorouracil combination
02
Targets
TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on PELF (cisplatin + epirubicin + leucovorin + 5-fluorouracil).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PELF (cisplatin + epirubicin + leucovorin + 5-fluorouracil).